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Intravenous Iron Reduces NT-Pro-Brain
Natriuretic Peptide in Anemic Patients With
Chronic Heart Failure and Renal Insufficiency
Jorge Eduardo Toblli, MD, PHD, Alejandra Lombraña, MD, Patricio Duarte, MD,
Federico Di Gennaro, MD
Buenos Aires, Argentina
Objectives Our objective was to evaluate in a double-blind, randomized, placebo-controlled study possible modifications in
NT-pro-brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) levels together with clinical and func-
tional parameters, in a group of anemic patients with chronic heart failure (CHF) and chronic renal failure (CRF)
receiving intravenous iron therapy, without recombinant human erythropoietin (rhEPO), versus placebo.
Background Chronic heart failure and CRF associated with absolute or relative iron deficiency anemia is a common problem.
This situation is linked with a variable inflammatory status. Both NT-proBNP and CRP are recognized markers for
left ventricular dysfunction and inflammatory status, respectively. In this double-blind, randomized, placebo-
controlled study, modifications in NT-proBNP and CRP level and clinical and functional parameters, in anemic
patients with CHF and CRF receiving intravenous iron therapy, without rhEPO, versus placebo were evaluated.
Methods Forty patients with hemoglobin (Hb) 12.5 g/dl, transferrin saturation 20%, ferritin 100 ng/ml, creatinine
clearance (CrCl) 90 ml/min, and left ventricular ejection fraction (LVEF) 35% were randomized into 2 groups
(n  20 for each). For 5 weeks, group A received isotonic saline solution and group B received iron sucrose com-
plex, 200 mg weekly. Minnesota Living with Heart Failure Questionnaire (MLHFQ) and 6-min walk (6MW) test
were performed. NT-pro brain natriuretic peptide and CRP were evaluated throughout the study. No patients re-
ceived erythroprotein any time.
Results After 6 months follow-up, group B showed better hematology values and CrCl (p  0.01) and lower NT-proBNP
(117.5  87.4 pg/ml vs. 450.9  248.8 pg/ml, p  0.01) and CRP (2.3  0.8 mg/l vs. 6.5  3.7 mg/l, p 
0.01). There was a correlation initially (p  0.01) between Hb and NT-proBNP (group A: r  0.94 and group B:
r  0.81) and after 6 months only in group A: r  0.80. Similar correlations were observed with Hb and CRP.
Left ventricular ejection fraction percentage (35.7  4.7 vs. 28.8  2.4), MLHFQ score, and 6MW test were all
improved in group B (p  0.01). Additionally, group B had fewer hospitalizations: 0 of 20 versus group A, 5 of
20 (p  0.01; relative risk  2.33).
Conclusions Intravenous iron therapy without rhEPO substantially reduced NT-proBNP and inflammatory status in anemic pa-
tients with CHF and moderate CRF. This situation was associated with an improvement in LVEF, NYHA functional
class, exercise capacity, renal function, and better quality of life. (J Am Coll Cardiol 2007;50:1657–65)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.029m
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hnquestionably, the use of therapy against the renin-
ngiotensin-aldosterone system, angiotensin-converting en-
yme inhibitors and angiotensin II type 1-receptor blockers,
See page 1666
nd beta-blockers, has favorably modified the prognosis of
hronic heart failure (CHF). However, the mortality and
rom the Hospital Alema´n, Buenos Aires, Argentina.e
Manuscript received March 23, 2007; revised manuscript received July 3, 2007,
ccepted July 8, 2007.orbidity in patients with CHF remains high (1,2). Despite
he fact that poor outcomes might, in part, be due to
nadequate choice or dosage of corresponding medications,
t is also possible that the presence of some comorbidity
uch as anemia could be an important contributing factor. In
upport of this, anemia is widely recognized as a common
omorbidity in patients with CHF (3–9). Almost one-third
f patients with CHF present with anemia (3–9), and this
ituation is associated with an increase in left ventricular
LV) mass, a greater incidence of rehospitalization, and
igher mortality (3–9). Absolute or relative iron and/or
rythropoietin (EPO) deficiency are involved in the patho-
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patients, especially when some
degree of chronic renal failure
(CRF) is present (10). Further-
more, occurrence of anemia in
these patients is also associated
with increasing NT-pro-brain
natriuretic peptide (NT-proBNP)
level and C-reactive protein
(CRP) (11,12), which are recog-
nized markers of LV dysfunction
and inflammatory status, respec-
tively. Therefore, a therapeutic
intervention, which increases he-
moglobin (Hb) concentrations
in these patients, may be of
importance.
In the last few years, some
small preliminary studies have
reported that correction of low Hb
concentrations by erythropoiesis-
stimulating proteins such as re-
combinant human erythropoietin
(rhEPO) or darbepoetin may sig-
nificantly improve cardiac and re-
al function and reduce the number of hospitalizations (13–
5). So far, only one study using intravenous (IV) iron without
PO in patients with CHF has been conducted (16). It was a
rospective, uncontrolled, open-label study with a follow-up of
months using iron sucrose complex (ISC) in which the
uthors reported a significant increase in Hb level and substan-
ial improvement in exercise capacity in anemic patients with
HF.
Against this background, the present double-blind, ran-
omized, placebo-controlled study was designed in order to
valuate as primary objectives: 1) the effectiveness of IV ISC
dministration without rhEPO therapy for improving he-
atologic and renal parameters; and 2) the change in the
T-proBNP level and inflammatory status by CRP in
atients with CHF and moderate CRF compared with that
n patients receiving only standard CHF therapy. The
econdary objectives were to determine the number of
ospitalizations, exercise tolerance, and change in the qual-
ty of life in these patients.
ethods
he local research and ethics committee granted study
pproval. Written, informed consent was obtained from all
articipants. This was a small, pilot, prospective, double-
lind, randomized, placebo-controlled study. The study
opulation was composed of adult patients of both genders.
The enrolled patients were not a specific or selected
roup. They were the consecutive patients from the general
opulation that spontaneously consulted the outpatient’s
Abbreviations
and Acronyms
6MW  6-min walk
BMI  body mass index
CHF  chronic heart failure
CRF  chronic renal failure
CRP  C-reactive protein
Hb  hemoglobin
ISC  iron sucrose
complex
IV  intravenous
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
NT-proBNP  NT-pro-brain
natriuretic peptide
NYHA  New York Heart
Association
rhEPO  recombinant
human erythropoietin
TSAT  transferrin
saturationffice of the cardiology section at the Hospital Alema´n duenos Aires, Argentina, and who fulfilled the inclusion
riteria for the study having a diagnosis of CHF, CRF,
nemia, and iron deficiency. Afterward, they were random-
zed and included in the study protocol.
nclusion criteria. Patients with: 1) LV ejection fraction
EF) 35%; 2) New York Heart Association (NYHA)
unctional class II to IV; 3) anemia with an iron deficit
efined by Hb 12.5 g/dl for men and 11.5 g/dl for
omen, and some of the following: serum ferritin 100
g/ml and/or with transferrin saturation (TSAT) 20%;
nd 4) creatinine clearance 90 ml/min were included in
he study.
xclusion criteria. Patients with: 1) hemodialysis therapy;
) anemia not due to iron deficiency available for erythro-
oiesis; 3) NYHA functional class I; 4) history of allergy to
he iron supplements; 5) acute bacterial infections,
arasitism known in the 4 previous weeks, and neoplasm; 6)
hronic digestive diseases; 7) hypothyroidism; 8) congenital
ardiopathies; 9) receiving iron supplements in the 4 previ-
us weeks; 10) receiving rhEPO in the 4 previous weeks;
nd 11) history of hospitalization during the 4 weeks before
nrollment into the study were excluded from the study.
Once the patients had signed the informed consent, 2
roups were created by random allocation of the total
opulation by means of a table of random numbers. One
roup (group A) received placebo in addition to conven-
ional therapy for the management of the CHF while group
received additional administration of IV ISC (Venofer,
ifor Int., St. Gallen, Switzerland) 200 mg weekly for 5
eeks. No patient received rhEPO before the study and at
ny time during the study. A complete medical history with
xhaustive physical examination was performed in each
atient recording data such as age, gender, body mass index
BMI), medication, blood pressure, heart rate, and breath-
ng rate. Symptoms were assessed according to NYHA
unctional classification. Complete blood count, serum fer-
itin, TSAT, NT-proBNP, CRP, creatinine clearance, and
lectrolytes were evaluated. Transthoracic echocardiogram,
innesota Living with Heart Failure Questionnaire
MLHFQ) (17,18), and 6-min walk (6MW) test (19) were
lso performed in each patient.
V iron administration. At each visit, the patient lay on a
tretcher and underwent a vein cannulation in the forearm
ith a commercial canula no. 16 (Abbott Laboratories,
bbott Park, Illinois), which was connected to IV tubing
hat was connected to a bag of isotonic saline solution 0.9%.
or the patients in group A (control group), the bag
ontained only 200 ml isotonic saline solution 0.9%,
hereas in group B (intervention group) the bag contained
00 mg/200 ml of ISC. Each infusion was administered
hroughout 60 min. The infusion was prepared by a nurse
efore its application, who then put a black cover around the
ag and the IV equipment so that neither the patient nor
he physician was aware of which therapy was being
dministered. In order to maintain the double-blind proce-
ure, the nurse who prepared the solution and put the black
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October 23, 2007:1657–65 IV Iron and NT-ProBNP in HFover around the bag and the IV equipment was not the
ame person who applied the infusion to the corresponding
atients. This scheme was followed for 5 consecutive weeks.
Once the 5-week treatment phase was completed, the
atients entered the follow-up phase in which monthly
heck-ups were carried out for the following 5 months.
ollow-up phase. Symptoms were assessed according to
YHA functional classification and MLHFQ. Exercise
apacity was quantified using a 6MW test with physicians
linded to the treatment. At each check-up, hematology
ariables and creatinine clearance were also measured.
chocardiography evaluation. At baseline, 3 months, and
months, transthoracic echocardiograms were obtained
sing an APLIO 80 (Toshiba, Tokyo, Japan) echocardio-
raphic system with the corresponding transducer (2.5
Hz). Left ventricular ejection fraction was assessed in 2-
nd 4-chamber views following the recommendations of the
merican Society of Echocardiography (20). All physicians
erforming the echocardiographic tests were blinded to the
reatment.
iochemical procedures. Hemoglobin was determined by
YSMEX XT 1800i (Roche Diagnostics, Basel, Switzer-
and). Serum transferrin was determined by radial immu-
odiffusion (Diffu-Plate; Biocientifica, S.A., Buenos Aires,
rgentina). Transferrin saturation (%) was obtained using a
hemical method. Serum iron and CRP were measured
sing an autoanalyzer Modular P800 (Roche Diagnostics)
ith the correspondent reagents (Roche Diagnostic GmbH,
annheim, Germany). The NT-proBNP was measured on
he Elecsys 2010 analyzer (Elecsys proBNP Immunoassay,
oche Diagnostics) (21). Creatinine clearance and serum
lectrolytes were assessed by standard methods.
tatistical method. All statistical analyses were processed
hrough GraphPad Prism, version. 4.0 (GraphPad Soft-
are, Inc., San Diego, California). When evaluating param-
ters with Gaussian distribution, comparisons were carried
ut using unpaired t test between the groups and paired
test within each group. For those parameters with non-
aussian distribution, such as NT-proBNP and CRP,
omparisons were performed by nonparametric methods
sing the Mann-Whitney test between the groups and the
ilcoxon matched pair test within each group. Spearman’s
orrelation was performed to determine the linear correla-
ion between Hb and NT-proBNP and CRP.
In order to evaluate relative risk, Fisher exact test with
5% confidence interval (using the approximation of Katz)
as performed. Values were expressed as mean  standard
eviation, and a value of p  0.05 was considered significant.
esults
he mean age of patients in the group A was 74  8 years
range 60 to 89 years) and in the group B 76  7 years
range 64 to 94 years). The etiology of CHF in the patient
opulation is listed in Table 1. pAt baseline, both groups presented nonsignificant differ-
nces between themselves concerning parameters evaluated
Table 2). Moreover, they were receiving similar medica-
ions for CHF (Table 3, top). Therapy with ISC was well
olerated in all patients, and there were no side effects
eported in the 2 groups throughout the study.
At the end of the study, significant increases in Hb level
s well as in the other hematology variables such as ferritin
nd TSAT were observed in patients in group B (Table 2,
ig. 1). These modifications appeared together with a
ignificant improvement in the renal function, expressed
AQ:9, and a higher creatinine clearance, with the values
eginning to be significant from the second month after IV
ron treatment, which corresponded to the third month of
he study, as shown in Figure 1. A better control in blood
ressure was similarly achieved in both groups at the end of the
tudy with respect to the baseline values (Table 2). Heart rate
nd BMI in group B were significantly (p  0.01) lower
ompared with those seen in group A as indicated in Table 2.
The NT-proBNP was markedly reduced (p  0.01) in
atients from group B as well as CRP (p 0.01) at the third
onth and at the end of the study in comparison with that
een in group A (Table 2, Fig. 2). There was a significant
p  0.01) negative correlation between Hb and NT-
roBNP at baseline in both groups, but only in group A at
he end of the study (Fig. 3). At the same time, there was
lso a significant (p  0.01) negative correlation between
b and CRP initially and at the end of the study in both
roups (Fig. 4). Concurrent with these findings, LVEF % in
atients from group B was significantly increased (p 0.01)
ompared with that in group A after the third month and at
he end of the study, as illustrated in Figure 2 and Table 2.
There was a favorable and significant (p  0.01) change
n NYHA functional class as well as in MLHFQ score in
roup B versus group A from baseline to the end of the
tudy, as indicated in Table 2. Although no major differ-
nces were observed regarding CHF medications in either
roup, patients in group B had lower diuretic requirements
p 0.05) compared with those in group A at the end of the
tudy (Table 3, bottom).
Concerning patient hospitalizations due to CHF, group
had 5 cases, while there were no hospitalizations because
f heart failure in group B (Table 2).
The evaluation of exercise capacity by 6MW test at the
nd of the study indicated a mild but not significant
eduction in the distance achieved during the test related to
he baseline records for patients in group A. However,
tiology of Congestive Heart Failure in the 2 Groups
Table 1 Etiology of Congestive Heart Failure in the 2 Groups
Group A (n  20) Group B (n  20)
Coronary artery disease 13 12
Cardiomyopathy 4 5
Hypertension 3 2
Aortic valve disease 0 1atients from group B showed a significant (p  0.01)
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IV Iron and NT-ProBNP in HF October 23, 2007:1657–65mprovement, not only compared with group A at the end
f the study, but also compared with baseline performance
Table 2).
iscussion
his is the first double-blind, randomized, placebo-
ontrolled study to evaluate effectiveness of IV ISC admin-
stration, without rhEPO supply, regarding hematology,
enal function, changes in NT-proBNP, inflammatory sta-
us, as well as the number of hospitalizations, exercise
Parameters Evaluated Throughout the Study
Table 2 Parameters Evaluated Throughout t
Base
Mean  SD
Group A
(n  20)
BMI (kg/m2) 29.0 3.4
Heart rate (beats/min) 80.5 8.1
Systolic blood pressure (mm Hg) 138.8 8.3
Diastolic blood pressure (mm Hg) 73.4 7.5
Hb (g/dl) 10.2 0.5
Ferritin (ng/ml) 70.6 21.4
TSAT (%) 0.20 0.01
NT-proBNP (pg/ml) 267.5 114.9
C-reactive protein (mg/l) 6.6 4.3
CrCl (ml/min) 37.7 10.2
EF (%) 30.8 1.7
NYHA functional class 2.9 0.6
MLHFQ score 58 6
6MW test (m) 190.7 56.1
Number of hospitalizations —
*p 0.01 versus group A at final; †p 0.01 versus group B at baselin
confidence interval 1.59 to 3.42).
BMI  body mass index; CrCl  creatinine clearance; EF  ejectio
Questionnaire; NT-proBNP  NT-pro-brain natriuretic peptide; NYHA 
walk.
atient Medication
Table 3 Patient Medication
CHF Medication Group A (n  20) Group B (n  20)
Baseline medication
Diuretics 19/20 19/20
ACE inhibitors 20/20 19/20
AT1 receptor blockers 4/20 5/20
Beta-blockers 20/20 20/20
Vasodilators (nitrites) 6/20 5/20
Digoxin 12/20 13/20
Aspirin 14/20 15/20
6-month follow-up medication
Diuretics 19/20 13/20*
ACE inhibitors 20/20 18/20
AT1 receptor blockers 5/20 5/20
Beta-blockers 20/20 20/20
Vasodilators (nitrites) 7/20 4/20
Digoxin 14/20 13/20
Aspirin 15/20 15/20i
p  0.05, relative risk  4.75 (95% confidence interval 0.74 to 30.39).
ACE  angiotensin-converting enzyme; AT1  angiotensin I; CHF  chronic heart failure.olerance, and change in quality of life of anemic patients
ith CHF and moderate CRF over a 6-month period.
The results obtained indicate that IV ISC therapy for 5
eeks significantly increased not only Hb concentrations
ut also ferritin and TSAT. Furthermore, renal function
valuated by creatinine clearance was also improved with
his treatment together with an increase in LVEF reduction
n NYHA functional class, a better quality of life, fewer
ospitalizations, and better exercise tolerance.
Despite the fact that the etiology of anemia in patients
ith advanced CHF is generally considered multifactorial,
ne of the most prevalent causes is iron deficiency. How-
ver, it is worth mentioning that, although Hb levels may be
ow in some patients with CHF, this can be due to a
ilution factor and may not necessarily be due to iron
eficiency per se. However, Nanas et al. (22) have reported
high proportion of patients with iron deficiency in their
ecent prospective study in nonelderly anemic patients with
evere CHF. This group concludes that the iron status of
atients with CHF should be thoroughly evaluated and
orrected before considering other therapeutic interventions.
In accordance with this report, patients in our current
tudy were receiving similar treatment for CHF at baseline
nd had similar LVEFs. Nevertheless, only those patients
ho received IV iron therapy displayed not only a better
esponse in clinical and laboratory variables explored
hroughout the follow-up period, but also a reduction in
iuretic consumption, which suggests an actual benefit in
he CHF management.
It is well known that anemia causes tissue hypoxia,
udy
Final (6-Month Follow-Up)
Group B
n  20)
Group A
(n  20)
Group B
(n  20)
.7 3.3 28.5 3.2 26.7 2.8*†
.7 8.2 76.3 10.4 67.5 5.9*†
.7 8.2 134.3 7.3‡ 135.7 6.1†
.4 9.6 70.2 6.6‡ 70.1 8.3†
.3 0.6 9.8 0.6 11.8 0.7*†
.0 29.9 78.9 30.1 240.4 55.6*†
20 0.01 0.20 0.01 0.25 0.04*†
.9 124.6 450.9 248.8‡ 117.5 87.4*†
.1 3.8 6.5 3.7 2.3 0.8*†
.8 10.1 31.7 10.8‡ 44.9 11.0*†
.3 3.7 28.8 2.4 35.7 4.7*†
.9 0.7 3.3 0.6‡ 2.0 0.2*†
60 5 59 8 41 7*†
.3 60.9 184.5 58.5 240.1 51.2*†
— 5/20§ 0/20
0.05 versus group A at baseline; §p 0.01 relative risk 2.33 (95%
n; Hb  hemoglobin; MLHFQ  Minnesota Living with Heart Failure
ork Heart Association; TSAT  transferrin saturation; 6MW  6-minhe St
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October 23, 2007:1657–65 IV Iron and NT-ProBNP in HFesponse, which stimulates sympathetic activity with a
ecrease in renal blood flow.
Consequently, the renin-angiotensin-aldosterone system
nd antidiuretic hormone are activated, producing sodium
nd fluid retention (23). As a result, patients in this situation
ave higher diuretic requirements and some may show
esistance to conventional CHF treatments. Reduction in
iuretic therapy in patients with CHF after an increase in
b concentration has already been described but only using
Figure 1 Hemoglobin Concentration, TSAT, and
Creatinine Clearance Throughout the Study
(A) Note that by the third month, there was a significant difference between
the groups in hemoglobin level. (B) There was a significant difference in trans-
ferrin saturation (TSAT) by the third month. (C) There was a significant differ-
ence in creatinine clearance by the third month between the groups.combination of rhEPO with IV iron or darbepoetin aloneut never before with IV iron therapy alone as observed in
ur study (14,15).
It is currently accepted that one of the most useful tests
or evaluating the status of patients with CHF is NT-
roBNP, not only for systolic but also for diastolic LV
ysfunction (11,24). A single measurement of NT-proBNP
n patients with advanced CHF can help to identify patients
ho are at a higher risk of death, and, in one study, it was
n even better prognostic marker than anemia (25). How-
ver, decreased concentrations of Hb are sufficient to pro-
uce serum concentrations of NT-proBNP above diagnostic
Figure 2 NT-proBNP, CRP, and LVEF
Evaluated in Both Groups Throughout the Study
(A) NT-pro-brain natriuretic peptide (NT-proBNP); (B) C-reactive protein (CRP);
and (C) left ventricular ejection fraction (LVEF) evaluated by echocardiogram in
both groups.
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IV Iron and NT-ProBNP in HF October 23, 2007:1657–65utoffs in anemic patients even without CHF. This is
ndependent of gender, BMI, renal function, LV hypertro-
hy, and/or valve disease (26). In the present study, IV iron
herapy substantially reduced NT-proBNP level, and there
as a significant negative correlation between Hb and
T-proBNP in both groups, not only at baseline but also at
he end of the study. Since Hb levels are independently
redictive of plasma NT-proBNP levels in patients with
ardiovascular disease even without (27) or with CHF
28,29), they may represent an important confounder of the
elationship between NT-proBNP, cardiac function, and
rognosis. In agreement with this statement, a recent
ultinational trial with a considerable number of patients
ith dyspnea who were treated in the emergency depart-
ent reported that, for men without CHF and diastolic
HF patients of both genders, a low Hb might be a
onfounding variable toward increasing NT-proBNP.
mong systolic CHF patients, the presence of a low Hb
oncentration was not a factor in the interpretation of
T-proBNP results (29).
Chronic heart failure and CRF are both states of persis-
ent inflammatory activation, and higher levels of circulating
roinflammatory cytokines, such as tumor necrosis factor-
nd interleukin-6, are known to be associated with greater
isease severity and worsened clinical outcomes (30–34).
It is likely that inflammation associated with both CHF
Figure 3 Relationship Between NT-proBNP and Hemoglobin Lev
A significant (p  0.01) negative correlation between these 2 variables was seen
at baseline (A), although only in group A at the end of the study (B). NT-proBNP nd CRF creates a vicious circle of inflammation, with each tmplifying the other. In addition, data from the Framing-
am Heart Study also suggest that an increase in CRP level
s associated with a 2-fold increased risk for CHF (35).
hronic hypoxia due to anemia may induce overexpression
f proinflammatory cytokines (tumor necrosis factor- and
nterleukin-6) (36), which are partially responsible for per-
etuating the inflammatory status in patients with CHF and
RF as well as potentiating the relative iron deficiency by
timulating hepcidin. This protein inhibits iron gastrointes-
inal absorption and also inhibits release of iron from iron
tores in the macrophages (37).
Iron deficiency is associated with multiple disturbances
ncluding disturbances in the cardiovascular system. Defi-
iency in iron availability may cause not only an inadequate
one marrow response to anemia but also structural alter-
tions in cardiomyocytes, as reported in experimental mod-
ls of iron deficiency (38). Recently, Dong et al. (39) have
eported important ultrastructural myocardial changes in a
roup of male rats fed with an iron-deficient diet. Ultra-
tructural examination revealed mitochondrial swelling and
bnormal sarcomere structure in iron-deficient ventricular
issues. Cytochrome c release was significantly enhanced in
hese animals. Moreover, protein expression of endothelial
itric oxide synthase and inducible nitric oxide synthase,
nd protein nitrotyrosine formation, were significantly ele-
ated in cardiac tissue or mitochondrial extraction. Addi-
Both Groups
groups
o brain natriuretic peptide.el in
in both
NT-prionally, a significant up-regulated reduced nicotinamide
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October 23, 2007:1657–65 IV Iron and NT-ProBNP in HFdenine dinucleotide phosphate oxidase, caveolin-1, and
hoA expression were also detected in ventricular tissue.
herefore, in a clinical scenario, we can speculate that IV
ron therapy in those patients with absolute or relative iron
eficiency may provide an additional benefit beyond im-
roving Hb level.
Since variable degrees of oxidative stress may be present
n the patients with CHF and chronic kidney disease,
ndoubtedly some concern about oxidative stress and other
ossible adverse effects caused by IV iron in these patients
ould be taken into account. However, the amount of iron
nfused and its effect on ferritin level as well as TSAT were
ot excessive in our study, as supported by the current
ecommendation for the management of anemic patients
ith chronic kidney disease and iron deficiency (40).
In the present study, at baseline, the inflammatory status,
s evaluated by CRP level, was similar in both groups.
owever, only the group with IV iron therapy showed a
ignificant reduction in CRP level at the end of the study.
his suggests a better control of inflammation in these
atients and probably, as a consequence, an improvement in
ron utilization by the bone marrow and possibly by the
itochondria of cardiomyocytes, this resulting in better
ardiac performance.
Mancini et al. (41) in a randomized single-blind study
ith a small number of nonelderly anemic patients with
Figure 4 Relationship Between CRP and Hemoglobin Level in B
A significant (p  0.01) negative correlation between these 2 variables in both groHF who were treated with rhEPO and oral iron versus tlacebo reported comparable positive results to those ob-
erved in our current study concerning Hb and exercise
olerance. Moreover, a recent study by Palazzuoli et al. (42)
n a randomized, double-blind, placebo-controlled study of
he combination of rhEPO and oral iron versus oral iron
lone in patients with anemia and resistant CHF, the
uthors concluded that the correction of anemia with EPO
nd oral iron leads to improvement in NYHA functional
lass, renal function, and plasma BNP levels and reduces
ospitalization. Furthermore, in various studies in patients
ith moderate-to-severe chronic kidney disease, IV iron
lone has successfully increased the Hb in this group
43–46).
It is also important to consider the superiority of IV over
ral iron therapy as seen in a recent study (47).
Lately, rhEPO therapy in anemic patients with stage 3 to
CRF has become controversial, due to a recent report
rom Singh et al. (48), the CHOIR (Correction of anemia
ith epoetin alfa in chronic kidney disease) study, in which
he authors found that when using a target Hb level of 13.5
/dl, as compared with 11.3 g/dl, the cardiovascular risk
ncreased without incremental improvement in the quality
f life. Despite a different number of patients in the
HOIR study in comparison with our small pilot study,
here are other discrepancies between these 2 trials, which
ave to be highlighted. The main differences were that in
roups
as seen initially (A) and at the end of the study (B). CRP  C-reactive protein.oth G
ups whe CHOIR study, the investigators focused on a cohort of
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IV Iron and NT-ProBNP in HF October 23, 2007:1657–65nemic patients with chronic kidney disease. Less than a
uarter of all the enrolled patients presented CHF, most
ith mean TSAT value higher than 25% and a mean
erritin value over 160 ng/ml. One-third were on iron
herapy but only a few were on IV iron. In addition, the
nflammatory status of the patients as well as details of LV
erformance by echocardiogram evaluation was unclear in
hat study. In our study, all the patients had CHF, a marked
nflammatory status, and a well-defined low LVEF.
Taking all these factors into account, treatment with
hEPO might not always be the first choice of therapy;
iving IV iron alone might be a better approach, not only for
ncreasing Hb levels but also perhaps to improve cardiac
erformance and life quality.
In various studies, including the present one, the im-
rovement in the Hb level in anemic patients with CHF
as unquestionably associated with a better quality of life
13,14,16,42). Even in the CREATE (Cardiovascular Risk
eduction by Early Anemia Treatment with Epoetin Beta)
rial (49), in which the authors reported that early complete
orrection of anemia (target level 13.0 to 15.0 g/dl) in patients
ith chronic kidney disease did not reduce the risk of cardio-
ascular events, they found at 2 years that the quality of life
general and mental health, and physical function) was signif-
cantly better in the group with a high Hb.
Finally, we conclude that the results presented in the
urrent study, together with the preliminary experience by
olger et al. (16), provide a new insight for a better
nderstanding of the pathophysiology of NT-proBNP and
he inflammatory status of anemic patients with CHF and
RF, who received IV iron therapy without rhEPO in
ddition to conventional treatment for CHF. Nevertheless,
s a limitation of the present study, we would like to point
ut that since this is a small study, it needs confirmation by
large well-powered, randomized, placebo-controlled trial
hat is mortality driven. Therefore, we consider that our
resent contribution is perhaps only one of the first steps on
he way to finding out the role of IV iron in the anemia
f CHF.
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